Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Inventory Average (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Inventory Average for 5 consecutive years, with $68.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory Average rose 45.92% year-over-year to $68.1 million, compared with a TTM value of $68.1 million through Dec 2025, up 45.92%, and an annual FY2025 reading of $58.4 million, up 34.29% over the prior year.
  • Inventory Average was $68.1 million for Q4 2025 at Xeris Biopharma Holdings, up from $67.4 million in the prior quarter.
  • Across five years, Inventory Average topped out at $68.1 million in Q4 2025 and bottomed at $16.2 million in Q4 2021.
  • Average Inventory Average over 5 years is $38.0 million, with a median of $38.5 million recorded in 2023.
  • The sharpest move saw Inventory Average surged 96.49% in 2023, then increased 17.96% in 2024.
  • Year by year, Inventory Average stood at $16.2 million in 2021, then skyrocketed by 38.62% to $22.4 million in 2022, then soared by 71.62% to $38.5 million in 2023, then increased by 21.19% to $46.6 million in 2024, then skyrocketed by 45.92% to $68.1 million in 2025.
  • Business Quant data shows Inventory Average for XERS at $68.1 million in Q4 2025, $67.4 million in Q3 2025, and $60.0 million in Q2 2025.